Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | PDE5A | O76074 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.35 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | ALDH1A2 | O94788 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5096224 | 1.00 | RIPK1 (0.43) | RIPK1TSHRMAOBMAOAPDE5A | |
| SCHEMBL4517479 | 1.00 | RIPK1 (0.43) | RIPK1TSHRMAOBMAOAPDE5A | |
| SCHEMBL4092429 | 0.84 | ALDH1A1 (0.45) | TSHRALDH1A1KDM4EKMT2ALMNA | |
| SCHEMBL5027850 | 0.81 | RIPK1 (0.42) | RIPK1TSHRMAOBMAOAPDE5A | |
| SCHEMBL4515248 | 0.80 | RIPK1 (0.45) | RIPK1TSHRMAOBMAOAALDH1A1 | |
| SCHEMBL4506032 | 0.80 | RIPK1 (0.45) | RIPK1TSHRMAOBMAOAALDH1A1 | |
| SCHEMBL2581555 | 0.80 | MGLL (0.31) | TSHRALDH1A1KMT2A | |
| SCHEMBL4503885 | 0.80 | ALDH1A1 (0.46) | TSHRALDH1A1KDM4EKMT2ALMNA | |
| SCHEMBL2581032 | 0.77 | RIPK1 (0.48) | RIPK1TSHRALDH1A1KDM4EKMT2A | |
| SCHEMBL4503119 | 0.76 | ALDH1A1 (0.41) | RIPK1TSHRMAOBMAOAPDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1953158-B1 | BICYCLIC CINNAMIDE COMPOUND | EISAI R&D MAN CO LTD (JP) | 2012-09-12 | — | — | EP | disclosed |
| US-20090181945-A1 | TWO CYCLIC CINNAMIDE COMPOUND | KIMURA TEIJI | 2009-07-16 | — | — | US | disclosed |
| EP-1953158-A1 | BICYCLIC CINNAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2008-08-06 | — | — | EP | disclosed |
| US-20070117839-A1 | Two cyclic cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181945-A1 | TWO CYCLIC CINNAMIDE COMPOUND | APP, BACE1, PSEN1 | RIPK1 4491/4885TSHR 4749/4885MAOB 1849/4885 |
| US-20070117839-A1 | Two cyclic cinnamide compound | APP, BACE1, PSEN1 | RIPK1 4491/4885TSHR 4749/4885MAOB 1849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.